You may have heard the term microdosing connected to certain psychedelic drugs
(Which is to say, this may be a story of more consumers spending less money at Hims & Hers.) Accentuating the positive, though, CEO Andrew Dudum insisted Hims & Hers is "not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform." More than just adding customers, Hims & Hers is entering new markets, expanding into new drug categories, and focusing on "comprehensive diagnostics" to help differentiate itself as a provider of personalized healthcare
This makes semaglutide a highly attractive candidate for further weight loss research
It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 biology the upstream context that applies across every GLP-1 program, whether you choose Ro, Remedy Meds, or another provider
Or some similar over-the-counter cough and cold medication